MRNA — Moderna Income Statement
0.000.00%
Last trade - 00:00- $10.52bn
- $3.56bn
- $3.24bn
- 84
- 37
- 10
- 39
Annual income statement for Moderna, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 803 | 18,471 | 19,263 | 6,848 | 3,236 |
| Cost of Revenue | |||||
| Gross Profit | 795 | 15,854 | 13,847 | 4,355 | 2,267 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,567 | 5,175 | 9,843 | 11,087 | 7,181 |
| Operating Profit | -763 | 13,296 | 9,420 | -4,239 | -3,945 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -745 | 13,285 | 9,575 | -3,942 | -3,607 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -747 | 12,202 | 8,362 | -4,714 | -3,561 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -747 | 12,202 | 8,362 | -4,714 | -3,561 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -747 | 12,202 | 8,362 | -4,714 | -3,561 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.96 | 28.3 | 20.1 | -8.6 | -8.44 |